Cargando…
Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study
PURPOSE: While much progress has been made in the treatment of breast cancer, cardiac complications resulting from therapy remain a significant concern. Both anthracyclines and novel targeted agents can inflict cardiac damage. The present study aimed to evaluate the difference between what it is cur...
Autores principales: | Gavila, J., Seguí, M. Á., Calvo, L., López, T., Alonso, J. J., Farto, M., Sánchez-de la Rosa, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215075/ https://www.ncbi.nlm.nih.gov/pubmed/27101413 http://dx.doi.org/10.1007/s12094-016-1508-y |
Ejemplares similares
-
Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study
por: Boceta, J., et al.
Publicado: (2016) -
Evaluation of early subclinical cardiotoxicity of chemotherapy in breast cancer
por: Alıcı, Hayri, et al.
Publicado: (2015) -
Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008) -
Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017) -
Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention
por: Cueva, J. F., et al.
Publicado: (2017)